Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol.
Newell-Price J, Fleseriu M, Pivonello R, Feelders RA, Gadelha MR, Lacroix A, Witek P, Heaney AP, Piacentini A, Pedroncelli AM, Biller BMK. Newell-Price J, et al. Among authors: pedroncelli am. J Endocr Soc. 2024 Nov 12;9(1):bvae201. doi: 10.1210/jendso/bvae201. eCollection 2024 Nov 26. J Endocr Soc. 2024. PMID: 39610378 Free PMC article.
Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).
Shimatsu A, Biller BM, Fleseriu M, Pivonello R, Lee EJ, Leelawattana R, Kim JH, Walia R, Yu Y, Liao Z, Piacentini A, Pedroncelli AM, Snyder PJ. Shimatsu A, et al. Among authors: pedroncelli am. Endocr J. 2024 Dec 2;71(12):1103-1123. doi: 10.1507/endocrj.EJ24-0153. Epub 2024 Aug 23. Endocr J. 2024. PMID: 39183039 Free article. Clinical Trial.
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
Pivonello R, Fleseriu M, Newell-Price J, Shimatsu A, Feelders RA, Kadioglu P, Tabarin A, Brue TC, Geer EB, Piacentini A, Pedroncelli AM, Biller BMK. Pivonello R, et al. Among authors: pedroncelli am. J Endocrinol Invest. 2024 Oct;47(10):2437-2448. doi: 10.1007/s40618-024-02359-6. Epub 2024 May 2. J Endocrinol Invest. 2024. PMID: 38696122 Free PMC article. Clinical Trial.
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.
Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P, Kietsiriroje N, Piacentini A, Pedroncelli AM, Samson SL. Feldt-Rasmussen U, et al. Among authors: pedroncelli am. Front Endocrinol (Lausanne). 2024 Mar 21;15:1250822. doi: 10.3389/fendo.2024.1250822. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38577574 Free PMC article. Clinical Trial.
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Feelders RA, Fleseriu M, Kadioglu P, Bex M, González-Devia D, Boguszewski CL, Yavuz DG, Patino H, Pedroncelli AM, Maamari R, Chattopadhyay A, Biller BMK, Pivonello R. Feelders RA, et al. Among authors: pedroncelli am. Front Endocrinol (Lausanne). 2023 Oct 9;14:1165681. doi: 10.3389/fendo.2023.1165681. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37876540 Free PMC article. Clinical Trial.
Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF, Feelders RA, Heaney AP, Paul M, Pedroncelli AM, Auchus RJ. Gadelha M, et al. Among authors: pedroncelli am. Front Endocrinol (Lausanne). 2023 Aug 23;14:1236465. doi: 10.3389/fendo.2023.1236465. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37680892 Free PMC article.
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O'Connell P, Izquierdo M, Pedroncelli AM, Pivonello R. Fleseriu M, et al. Among authors: pedroncelli am. Pituitary. 2022 Dec;25(6):959-970. doi: 10.1007/s11102-022-01280-6. Epub 2022 Oct 11. Pituitary. 2022. PMID: 36219274 Free PMC article. Clinical Trial.
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, Belaya Z, Feelders RA, Vila G, Houde G, Walia R, Izquierdo M, Roughton M, Pedroncelli AM, Biller BMK. Fleseriu M, et al. Among authors: pedroncelli am. Eur J Endocrinol. 2022 Sep 16;187(4):531-541. doi: 10.1530/EJE-22-0317. Print 2022 Oct 1. Eur J Endocrinol. 2022. PMID: 35980235 Free PMC article.
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ. Gadelha M, et al. Among authors: pedroncelli am. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2882-e2895. doi: 10.1210/clinem/dgac178. J Clin Endocrinol Metab. 2022. PMID: 35325149 Free PMC article. Clinical Trial.
27 results